RaQualia Pharma

Stock Market Tokyo Stock Exchange: Growth Market
Security Code 4579
Website RaQualia Pharma Website

RaQualia Pharma Research Report

Pipelines

Updated on 12 18, 2024

Completed
On planning
On going
Launch
Plan
Program Compound code
(Generic name)		 Indication Partnered party Discovery Pre-Clin, Clinical Trial NDA Approval Launch Territory Remarks
Phase 1 Phase 2 Phase 3
Potassium-Competitive Acid Blocker
(P-CAB)		 RQ-00000004
(Tegoprazan)
IN-12420 [HK inno.N]
LXI-15028 [Luoxin Pharma]
BLI5100 [Braintree Laboratories]		 GERD
(ERD/NERD)
Gastric Ulcer
H. pylori Treatment		 -
Completed P1
 Japan
HK inno.N
On going P3 (EE, NERD)
 USA Re-contracted: HK inno.N => Braintree Laboratories (Including Canada)
Launch
 Korea
China
Philippines
Mongolia
Mexico
Peru
Chile
Colombia
Dominican Republic
Nicaragua
Honduras
Guatemala
El Salvador
Indonesia
Singapore		 [Korea]
Product name: K-CAB
---
[China]
Product name: 泰欣赞
Re-contracted: HK inno.N => Luoxin Pharma
---
[Philippines]
Re-contracted: HK inno.N => Metro Pharma Phils
---
[Mongolia]
Re-contracted: HK inno.N => Monos Pharma
---
[Mexico, Peru, Chile, Colombia, Dominican Republic, Nicaragua, Honduras, Guatemala, El Salvador]
Product name: Ki-CAB
Re-contracted: HK inno.N => Laboratorios Carnot
---
[Indonesia]
Product name: TEZA
Re-contracted: HK inno.N => Kalbe Farma
---
[Singapore]
Re-contracted: HK inno.N => United Italian Trading Corporation (UITC)
Vietnam Re-contracted: HK inno.N => Lynh Pharma
Thailand Re-contracted: HK inno.N => Pond's Chemical Thailand R.O.P.
Malaysia Pharmaceutical supply contract: HK inno.N => Pharmaniaga Logistics
Latin America
8 countries
(Argentina etc.)		 Re-contracted: HK inno.N => Laboratorios Carnot
Brazil Re-contracted: HK inno.N => Eurofarma Laboratórios S.A.
India
South Africa
Asia and Eastern Europe: 5 countries		 Re-contracted: HK inno.N => Dr. Reddy's Laboratories
Middle East and North Africa (MENA): 17 countries Re-contracted: HK inno.N => Tabuk Pharmaceutical
All countries except the above
P2X7 Receptor Antagonist RQ-00466479
AK1780 [Asahi Kasei Pharma]
LY3857210 [Eli Lilly and Company]		 Pain - Asahi Kasei Pharma
- Eli Lilly and Company
On going P2
(U.S., etc.)
 Global Contracted: Asahi Kasei Pharma => Eli Lilly and Company [Reference]
Diabetic neuropathic medicine, herpes virus infective neuropathic medicine. [Reference]
TRPV4 Antagonist RQ-00317310 eye - Japan Compounds created through collaborative research with Gifu Pharmaceutical University.
TRPM8 Blocker RQ-00434739
XG2002 [Xgene]		 Pain Xgene Pharmaceutical
On going P1
(Australia)
 Global excluding Japan
Pain -
On planning
 Japan
Selective Sodium Channel Blocker - Pain
Itch		 - Clinical stage -
Sodium Channel Blocker RQ-00350215 Pain Hisamitsu Pharmaceutical
On going
 Global
Specific Ion Channel - Gastrointestinal Tract EA Pharma Undisclosed Global
AI - Intractable/Rare Disease SOCIUM
(Collaborative Research)
On going
 -
- - Intractable/Rare Disease STAND Therapeutics
(Collaborative Research)
On going
 -
Ion Channel - eye D. Western Therapeutics Institute
(Collaborative Research)
On going
 -
mRNA - Cancer Veritas In Silico
(Collaborative Research)
On going
 -
Ion Channel - - leadXpro
(Collaboration)
On going
 -
5-HT4 Partial Agonist RQ-00000010
VBX-3000 [Vetbiolix]		 Gastroparesis
Functional dyspepsia
Chronic Constipation		 -
On planning P2
 - Mosapride's sales amount of peak tops is 21.2 billion yen (Japan)
Gut motility disorders: Dog/Cat Vetbiolix PoC Global
RQ-00000009
AAT-009 [AskAt]		 Alzheimer's AskAt
(Global)
Completed P1
 USA
5-HT2B Antagonist RQ-00310941 IBS-D -
On planning P2
 -
Motilin Receptor Agonist RQ-00201894 Gastroparesis
Functional Dyspepsia
Post-Operative Ileus		 -
On planning P1
 Japan
Ghrelin Receptor Agonist RQ-00000005
（Capromorelin）
AT-002 [Elanco]		 Appetite Stimulation: Dog Elanco Animal Health
(Global (Animal))
Launch (October 2017)
 USA Product name (Dog): Entyce
Product name (Cat): Elura
Management of Weight Loss with CKD: Cat
Launch
 USA
France
Japan
RQ-00433412 Cancer-Related Anorexia/Cachexia Syndrome
SCI-associated Constipation		 -
On going
 Japan
EP4 Antagonist RQ-00000007
（Grapiprant）
AAT-007 [AskAt]
AT-001 [Elanco]
IK-007 [Ikena]
RMX1002 [RMX]
3D1002 [3D Medicines]		 Osteoarthritis: Dog Elanco Animal Health
(Global (Animal))
Launch (USA: 2017, Europe: 2019, Brazil, Japan: 2020)
 USA
Europe
Brazil
Japan		 Product name: Galliprant
MSS Colorectal Cancer
(MSS-CRC)		 AskAt
(Global (Excluding animal))
Completed P1
 USA
Metastatic Inflammatory Breast Cancer
(IBC)
IIT
 USA
Cancer
On going P1
 China Re-contracted: AskAt => Ningbo Tai Kang Medical Technology
Development: Ningbo NewBay Medical Technology
Pain
Completed P2a
 USA
Completed P1
 China Re-contracted: AskAt => RMX Biopharma (Merged with Haihe BioPharma)
Haihe => 3D Medicines
RQ-00000008
AAT-008 [AskAt]		 Cancer AskAt
(Global)
Completed
 USA
In preparation P1
 China Re-contracted: AskAt => Ningbo NewBay Medical Technology
COX-2 Inhibitor RQ-00317076
AAT-076 [AskAt]
RMX1001 [RMX]
3D1001 [3D Medicines]		 Pain AskAt
(Global)
Completed P2a
 USA
On going P1
 China Re-contracted: AskAt => RMX Biopharma (Merged with Haihe BioPharma)
Haihe => 3D Medicines
Pain
(Animal)
In preparation Pilot Study
 Global Re-contracted: AskAt => Velo-1
CB2 Receptor Agonist RQ-00202730
AAT-730 [AskAt]
OCT461201 [OCT]		 Pain AskAt
(Global)
Completed P1
 UK Re-contracted: AskAt => Oxford Cannabinoid Technologies (OCT) (Global excluding Japan)
Pain
Neuronal Diseases
Completed
 Japan
Certain four compounds - - Velovia Pharma
(Global (Animal))		 Global
Echinocandin antifungal
(Anidulafungin)		 Anidulafungin Candida Infections - Japan US product name: Eraxis
Glycopeptide anti-MRSA antibiotic
(Dalbavancin)		 Dalbavancin MRSA Infections - Japan US product name: Dalvance
Ion Channel - - -
On going
 -
- - -
On going
 -
- - -
On going
 -

Other Contracts

Updated on 4 25, 2023

Contractor Contract contents Remarks
H. Lundbeck A/S
(Denmark)		 RaQualia Grants Patent License to H. Lundbeck
Shire AG
(Swiss)		 RaQualia Grants a Non-Exclusive Patent License to Shire AG For the Use of Ghrelin Receptor Agonist
- RaQualia Pharma Joins DeNA & DeNA Life Science AI-Powered Drug Discovery Research Collaboration Press release
leadXpro AG Collaboration to Accelerate Drug Discovery on Intractable Membrane Protein Targets Press release

University Collaborative Research

Updated on 2 14, 2023

RaQualia Pharma Industry-Academia Collaborative Research Center

University Department Research theme Remarks
Gifu Pharmaceutical University Molecular Pharmacology, Department of Biofunctional Evaluation Evaluation of efficacy of a specific compound on retinal vein occlusion (RVO)

TMRC (subsidiary) Pipeline

Updated on 11 13, 2024

Completed
On planning
On going
Launch
Plan
Program Compound code
(Generic name)		 Indication Partnered party Discovery Pre-Clin, Clinical Trial NDA Approval Launch Territory Remarks
Phase 1 Phase 2 Phase 3
TM-411 TM-411
(Tamibarotene)
SY-1425 [Syros Pharmaceuticals]
OP-09 [Ohara Pharmaceutical]		 Newly Diagnosed HR-MDS Syros Pharmaceuticals USA Combination with azacitidine. Reference.
Neuroblastoma
(NB)		 Ohara Pharmaceutical
On going P1/2
 Japan
Pancreatic Cancer
(PC)		 IIT
(Nagoya University)
On going P1/2
 Japan
Acute promyelocytic leukemia
(APL)		 Toko Pharmaceutical Industrial
NDA
 China
Neutropenia
(NP)		 -
Completed
 USA

TMRC (subsidiary) Pipeline

Updated on 2 14, 2024

Completed
On planning
On going
Launch
Plan
Program Compound code
(Generic name)		 Indication Partnered party Discovery Pre-Clin, Clinical Trial NDA Approval Launch Territory Remarks
Phase 1 Phase 2 Phase 3
IRAK-M FIM-001 Non-small cell lung cancer
Pancreatic cancer
(Cancer immunity) etc.		 -
On going
 -
TRIB1 - Oncology -
On going
 -
Early stage project - Oncology -
On going
 -
- - Oncology Astellas Pharma
On going
 -
- - Oncology Astellas Pharma
On going
 -

Subsidiary

Updated on 2 14, 2024

Company name
TMRC Co., Ltd.
FIMECS, Inc.

Because of the personal survey, there are cases where the information on this site is "different from the fact" due to business content change or misunderstanding etc.
Therefore, please do not use for investment judgment. Also, this site is not intended to solicit investment.

Advertisements